Home/Filings/4/0001209191-22-017061
4//SEC Filing

Shani Eli 4

Accession 0001209191-22-017061

CIK 0000818686other

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 4:13 PM ET

Size

13.9 KB

Accession

0001209191-22-017061

Insider Transaction Report

Form 4
Period: 2022-03-04
Shani Eli
EVP,Global Marketing&Portfolio
Transactions
  • Award

    Restricted Share Units

    2022-03-04+80,42880,428 total
    Ordinary Shares (80,428 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2022-03-04+3,17312,264 total
  • Exercise/Conversion

    Restricted Share Units

    2022-03-043,1733,173 total
    Ordinary Shares (3,173 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2022-03-05+5,89618,160 total
  • Exercise/Conversion

    Restricted Share Units

    2022-03-055,89617,690 total
    Ordinary Shares (5,896 underlying)
Footnotes (5)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023.
  • [F4]Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
  • [F5]Restricted share units were granted on March 5, 2021, with 5,896 having vested on March 5, 2022, 5,896 vesting on each of March 5, 2023 and March 5, 2024, and 5,898 vesting on March 5, 2025.

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001876642

Filing Metadata

Form type
4
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:13 PM ET
Size
13.9 KB